Merrimack Pharmaceuticals Statistics Share Statistics Merrimack Pharmaceuticals has 14.79M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 14.79M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 9.66M Failed to Deliver (FTD) Shares 278,235 FTD / Avg. Volume 152.35%
Short Selling Information The latest short interest is 861.32K, so 0% of the outstanding
shares have been sold short.
Short Interest 861.32K Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 1.86
Valuation Ratios The PE ratio is -162.36 and the forward
PE ratio is null.
Merrimack Pharmaceuticals's PEG ratio is
6.52.
PE Ratio -162.36 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio 10.23 P/FCF Ratio -125.99 PEG Ratio 6.52
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Merrimack Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 43.5,
with a Debt / Equity ratio of 0.
Current Ratio 43.5 Quick Ratio 43.5 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee n/a Employee Count 0 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax 12K Effective Tax Rate -1.03%
Stock Price Statistics The stock price has increased by 0.07% in the
last 52 weeks. The beta is 1.42, so Merrimack Pharmaceuticals's
price volatility has been higher than the market average.
Beta 1.42 52-Week Price Change 0.07% 50-Day Moving Average 14.86 200-Day Moving Average 13.46 Relative Strength Index (RSI) 78.97 Average Volume (20 Days) 182,633
Income Statement
Revenue n/a Gross Profit n/a Operating Income -2.18M Net Income -1.18M EBITDA -2.18M EBIT n/a Earnings Per Share (EPS) -0.08
Full Income Statement Balance Sheet The company has 5.99M in cash and 0 in
debt, giving a net cash position of 5.99M.
Cash & Cash Equivalents 5.99M Total Debt n/a Net Cash n/a Retained Earnings -548.82M Total Assets 244.32M Working Capital 221.65M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -1.52M
and capital expenditures 0, giving a free cash flow of -1.52M.
Operating Cash Flow -1.52M Capital Expenditures n/a Free Cash Flow -1.52M FCF Per Share -0.11
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields MACK does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for MACK.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Sep 6, 2019. It was a
forward
split with a ratio of 1271:1000.
Last Split Date Sep 6, 2019 Split Type forward Split Ratio 1271:1000
Scores Altman Z-Score 4.99 Piotroski F-Score 2
